Peter Wostyn: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(expanded)
(added study)
Line 6: Line 6:


==Notable studies==
==Notable studies==
* 2018, Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?<ref>{{Cite journal|last=Wostyn|first=Peter|author-link=|last2=De Deyn|first2=Peter Paul|author-link2=|last3=|first3=|author-link3=|last4=|first4=|author-link4=|last5=|first5=|author-link5=|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Sep 2018|title=Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?|url=https://linkinghub.elsevier.com/retrieve/pii/S0306987718302895|journal=Medical Hypotheses|language=en|volume=118|issue=|pages=174|doi=10.1016/j.mehy.2018.04.020|pmc=|pmid=|access-date=|quote=|via=}}</ref>
* 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy<ref name=":0">{{Cite journal|last=Wostyn|first=Peter|author-link=|last2=De Deyn|first2=Peter Paul|author-link2=|last3=|first3=|author-link3=|last4=|first4=|author-link4=|last5=|first5=|author-link5=|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Sep 2018|title=The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy|url=https://linkinghub.elsevier.com/retrieve/pii/S0306987718305486|journal=Medical Hypotheses|language=en|volume=118|issue=|pages=142–145|doi=10.1016/j.mehy.2018.07.007|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [[pubmed:30037603|(Abstract)]]
* 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy<ref name=":0">{{Cite journal|last=Wostyn|first=Peter|author-link=|last2=De Deyn|first2=Peter Paul|author-link2=|last3=|first3=|author-link3=|last4=|first4=|author-link4=|last5=|first5=|author-link5=|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Sep 2018|title=The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy|url=https://linkinghub.elsevier.com/retrieve/pii/S0306987718305486|journal=Medical Hypotheses|language=en|volume=118|issue=|pages=142–145|doi=10.1016/j.mehy.2018.07.007|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [[pubmed:30037603|(Abstract)]]



Revision as of 22:00, October 22, 2019

Peter Wostyn, MD, works in the Department of Psychiatry, Psychiatrisch Centrum Sint-Amandus, Beernem, Belgium[1] and is a co-founder of P&X Medical, a biotech company focused on the treatment of intracranial pressure, cerebrospinal fluid turnover and glymphatic flow in neurodegenerative disorders, with a primary focus on glaucoma.[2]

Dr Wostyn developed the glymphatic dysfunction hypothesis which postulates that a dysfunction of the waste clearance system, called the glymphatic system, causes a build-up of toxins within the central nervous system, which precipitates at least some cases of chronic fatigue syndrome.[3]


Notable studies[edit | edit source]

  • 2018, Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?[4]
  • 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy[3] - (Abstract)
  • 2019, Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction[5]

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Peter Wostyn". LinkedIn. October 22, 2019. Cite has empty unknown parameter: |dead-url= (help)
  2. "Technology - P&X Medical". www.px-medical.be. Retrieved October 22, 2019.
  3. 3.0 3.1 Wostyn, Peter; De Deyn, Peter Paul (September 2018). "The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy". Medical Hypotheses. 118: 142–145. doi:10.1016/j.mehy.2018.07.007.
  4. Wostyn, Peter; De Deyn, Peter Paul (September 2018). "Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?". Medical Hypotheses. 118: 174. doi:10.1016/j.mehy.2018.04.020.
  5. Wostyn, Peter (October 4, 2019). "Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction". Medical Hypotheses. 134: 109416. doi:10.1016/j.mehy.2019.109416. ISSN 1532-2777. PMID 31622921.